Research programme: eye disorder therapeutics - pSivida/Undisclosed company

Drug Profile

Research programme: eye disorder therapeutics - pSivida/Undisclosed company

Latest Information Update: 24 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Undisclosed
  • Developer pSivida; Undisclosed
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Eye disorders

Most Recent Events

  • 12 May 2015 pSivida and an undisclosed leading global pharmaceutical company agree to evaluate Durasert™ drug delivery technology for eye disorder therapeutics
  • 12 May 2015 Early research in Eye disorders in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top